Disease-Free Survival
"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 | | 1997 | 0 | 6 | 6 | | 1998 | 0 | 9 | 9 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 6 | 6 | | 2001 | 0 | 8 | 8 | | 2002 | 0 | 11 | 11 | | 2003 | 0 | 6 | 6 | | 2004 | 0 | 7 | 7 | | 2005 | 0 | 11 | 11 | | 2006 | 0 | 10 | 10 | | 2007 | 0 | 14 | 14 | | 2008 | 0 | 19 | 19 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 31 | 31 | | 2011 | 0 | 20 | 20 | | 2012 | 0 | 32 | 32 | | 2013 | 0 | 43 | 43 | | 2014 | 0 | 40 | 40 | | 2015 | 0 | 50 | 50 | | 2016 | 0 | 45 | 45 | | 2017 | 0 | 66 | 66 | | 2018 | 0 | 35 | 35 | | 2019 | 0 | 42 | 42 | | 2020 | 0 | 25 | 25 | | 2021 | 0 | 13 | 13 | | 2022 | 0 | 12 | 12 | | 2023 | 0 | 9 | 9 | | 2024 | 0 | 5 | 5 | | 2025 | 0 | 11 | 11 | | 2026 | 0 | 13 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Zhang BX, Sella T, Zheng Y, Kirkner GJ, Ruddy KJ, Rosenberg SM, Borges VF, Schapira L, Come SE, Peppercorn JM, Collins L, Partridge AH, Brantley KD. Delays in breast cancer presentation, diagnosis, and treatment in young women. Cancer. 2026 Oct 15; 132(20):e70594.
-
Nader-Marta G, Zheng Y, Rosenberg SM, Dibble KE, Mayer EL, Poorvu PD, Ruddy KJ, Guzman-Arocho YD, Collins LC, Peppercorn J, Schapira L, Valenza C, Borges VF, Tayob N, Come SE, Warner E, Polyak K, Winer EP, Partridge AH. Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer. J Natl Cancer Inst. 2026 Oct 01; 118(10):1933-1941.
-
Abramson JS, Siddiqi T, Gordon LI, Lunning M, Wang M, Arnason J, Kamdar M, Maloney DG, Shadman M, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Hidalgo-López JE, Wang J, Ding X, Ogasawara K, Singh A, Palomba ML. Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study. Blood. 2026 09 10; 148(11):1388-1393.
-
Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026 Oct 20; 44(30):2919-2928.
-
Rich BS, Fishbein JS, Purcell LN, Murphy JT, Castle SL, Ghanbari N, Zohrabian A, Lautz TB, Kacey W, Post G, Thangarajah H, West E, Roach JP, Corkum KS, Perry T, Piché N, Roy M, Stafman LL, Dixon SM, Glithero KJ, Pittman ME, Çeliker MY, Grant CN, Sharf T, Tracy ET, Wachsmuth LP, Rustad A, Newman EA, Williams K, Wunker CM, Glick RD, Dasgupta R, Wilson S, Vore E, Cromeens BP, Turk F, Shaffiey SA, Alkhoury F, Goyal J, Brown EG, Seemann NM, Wilson CA, Davidson J, Polites SF, Parrish MT, Cameron DB, Stetson A, Gold RM, Aldrink JH, Mansfield SA, Srivatsa S, Christison-Lagay E, Rehman SU, Fialkowski EA, Selesner L, Larsen A, Le HD, Tracy SA, Ahmed T, Dimmer A, Malek MM, Campwala I, Colangelo A, Rothstein DH, Nchinda NN, Mattei P, Jain S, Hwang R, Craig BT, Lal DR, Abrebese E, Rhee DS, Chidiac C, Peters M, Boehmer C, Billmire DF. Immature teratoma of the ovary with microscopic yolk sac tumor in children and adolescents: A multi-institutional study. Gynecol Oncol. 2026 Aug; 211:125-131.
-
Morganti S, Kim SE, Jin Q, Cha J, Zeigler JE, Newman AB, Kirkner GJ, Snow C, Zheng Y, Vincuilla J, Parker T, Buehler RM, Bychkovsky BL, Dibble KE, Sella T, Ruddy KJ, Rosenberg SM, Collins LC, Peppercorn J, Schapira L, Borges VF, Guzman-Arocho YD, Come SE, Warner E, Poorvu PD, Lambertini M, Curigliano G, Hughes ME, Mittendorf EA, King TA, Lin NU, Garber JE, Tayob N, Tolaney SM, Partridge AH, Lynce F. Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies. JNCI Cancer Spectr. 2026 Jul 07; 10(4).
-
El Adel S, Jaradat D, Hoogteijling TJ, Koh YX, Cacciaguerra AB, Conci S, Aghayan D, Casellas M, Magistri P, Osei-Bordom D, Rusolillo N, de Meyere C, Zozaya G, Fisenko D, Ardito F, Lopez-Lopez V, Ahmad J, White S, Schmelzle M, Gallagher T, Sparrelid E, Sucandy I, Serrano PE, Geller D, Alseidi A, Croner RS, Dagher I, Primrose JN, Jovine E, Vrochides D, Memeo R, Daradka KIM, Besselink MG, Swijnenburg RJ, Robles-Campos R, Giuliante F, Efanov M, Rotellar F, D'Hondt M, Ferrero A, Sutcliffe RP, Di Benedetto F, López-Ben S, Edwin B, Ruzzenente A, Vivarelli M, Goh BKP, Hilal MA. Anatomical versus non-anatomical liver resection for hepatocellular carcinoma - an international multicenter propensity score-matched analysis of short- and long-term outcomes in an international multicenter cohort. HPB (Oxford). 2026 09; 28(9):1171-1181.
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 03 19; 147(12):1289-1301.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|